Notably, TF acts as a supplementary antiviral adjuvant in avian vaccines: when co-administered with Newcastle disease vaccines, it elevates antibody titers, extends immune protection, and reduces viral shedding by enhancing CTL activity and NK cell function [10]; combining TF with CpG ODNs also increases peripheral blood CD8+ CTLs by 18–22% to overcome virus-induced immune tolerance [9,10]—a key advantage for REV, which evades host immunity via T cell suppression [11,12]. The gene discussed is TF; the disease is Newcastle disease.